CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal Pharmaceuticals team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.
We offer our deepest condolences to Stephen’s family for their loss.
Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent innovations and achievements we’ve seen in NASH research stemmed from his constant collaboration with partners in academia, industry, the regulatory sciences, and the patient community.
Stephen was much more than a brilliant investigator and physician; he was a true leader who inspired all of us with his commitment to patients. We’ll remember his sense of humor, his courtesy, and his boundless energy and optimism.
The field of hepatology has lost a true giant.
Last Trade: | US$274.10 |
Daily Change: | -5.22 -1.87 |
Daily Volume: | 289,146 |
Market Cap: | US$5.980B |
May 01, 2025 April 29, 2025 March 11, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load